DSS (DSS) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 03, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-32146
Entity Registrant Name	DSS, INC.
Entity Central Index Key	0000771999
Entity Tax Identification Number	16-1229730
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	(585)
Local Phone Number	325-3610
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	DSS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		140,264,250

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 13,732,000	$ 19,290,000
Accounts receivable, net	6,995,000	7,564,000
Inventory	7,262,000	7,721,000
Current portion of notes receivable	11,422,000	11,719,000
Prepaid expenses and other current assets	2,043,000	1,700,000
Total current assets	41,454,000	47,994,000
Property, plant and equipment, net	13,611,000	13,391,000
Investment in real estate, net	54,511,000	55,029,000
Other investments	1,562,000	1,534,000
Investment, equity method	157,000	162,000
Marketable securities	13,391,000	27,307,000
Notes receivable	158,000	922,000
Other assets	2,754,000	2,699,000
Right-of-use assets	8,203,000	8,219,000
Goodwill	60,919,000	60,919,000
Other intangible assets, net	30,030,000	30,740,000
Total assets	226,750,000	248,916,000
Current liabilities:
Accounts payable	5,095,000	5,914,000
Accrued expenses and deferred revenue	9,461,000	19,341,000
Other current liabilities	477,000	477,000
Current portion of lease liability	800,000	796,000
Current portion of long-term debt, net	48,773,000	47,161,000
Total current liabilities	64,606,000	73,689,000
Long-term debt, net	5,778,000	10,181,000
Long term lease liability	7,773,000	7,820,000
Other long-term liabilities	507,000	507,000
Deferred tax liability	38,000	38,000
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $.02 par value; 47,000 shares authorized, 0 shares issued and outstanding (0 on December 31, 2022); Liquidation value $1,000 per share, zero aggregate on December 31, 2022).
Common stock, $.02 par value; 200,000,000 shares authorized, 139,017,172 shares issued and outstanding (139,017,172 on December 31, 2022)	2,779,000	2,779,000
Additional paid-in capital	317,126,000	317,126,000
Accumulated Deficit	(202,378,000)	(194,343,000)
Total Stockholder’s Equity	117,527,000	125,562,000
Non-controlling interest in subsidiaries	30,521,000	31,119,000
Total stockholders’ equity	148,048,000	156,681,000
Total liabilities and stockholders’ equity	$ 226,750,000	$ 248,916,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.02	$ 0.02
Preferred stock, shares authorized	47,000	47,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference per share		$ 1,000
Preferred stock, liquidation preference		$ 0
Common stock, par value	$ 0.02	$ 0.02
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	139,017,172	139,017,172
Common stock, shares outstanding	139,017,172	139,017,172

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 11,926,000	$ 12,304,000
Costs and expenses:
Cost of revenue	8,533,000	8,878,000
Selling, general and administrative (including stock-based compensation)	8,973,000	10,745,000
Total costs and expenses	17,506,000	19,623,000
Operating loss	(5,580,000)	(7,319,000)
Other income (expense):
Interest income	130,000	156,000
Dividend Income	4,000
Other income (expense)	(65,000)	(1,703,000)
Interest expense	(249,000)	(802,000)
Loss on equity method investment	(4,000)	(112,000)
Loss on investments	(2,869,000)	424,000
Gain on sale of asset		405,000
Loss from operations before income taxes	(8,633,000)	(8,951,000)
Income tax
Net loss	(8,633,000)	(8,951,000)
(Gain) loss from operations attributed to noncontrolling interest	598,000	903,000
Net loss attributable to common stockholders	$ (8,035,000)	$ (8,048,000)
Loss per common share:
Basic	$ (0.06)	$ (0.10)
Diluted	$ (0.06)	$ (0.10)
Shares used in computing loss per common share:
Basic	139,017,172	84,626,847
Diluted	139,017,172	84,626,847
Printed Products [Member]
Revenue:
Total revenue	$ 6,130,000	$ 3,569,000
Rental Income [Member]
Revenue:
Total revenue	1,685,000	1,663,000
Management Fee Income [Member]
Revenue:
Total revenue		11,000
Net Investment Income [Member]
Revenue:
Total revenue	117,000	129,000
Direct Marketing [Member]
Revenue:
Total revenue	$ 3,994,000	$ 6,932,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss from continuing operations	$ (8,633,000)	$ (8,951,000)
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:
Depreciation and amortization	1,333,000	3,266,000
Stock based compensation		4,000
Loss on equity method investment		(112,000)
Loss on investments	2,869,000	424,000
Change in ROU assets	16,000
Change in ROU liabilities	(43,000)
Impairment of notes receivable and other investments		1,637,000
Decrease (increase) in assets:
Accounts receivable	608,000	(430,000)
Inventory	459,000	602,000
Prepaid expenses and other current assets	(383,000)	1,597,000
Other assets	(55,000)	(68,000)
Increase (decrease) in liabilities:
Accounts payable	(819,000)	532,000
Accrued expenses	(9,551,000)	(4,697,000)
Other liabilities		126,000
Net cash used by operating activities	(14,199,000)	(6,070,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(594,000)	(942,000)
Purchase of investment		(1,085,000)
Purchase of marketable securities		(4,693,000)
Sale of marketable securities	11,330,000
Disposal of property, plant and equipment	32,000	2,152,000
Change in equity investment	5,000
Payments received on notes receivable	764,000
Issuance of new notes receivable, net origination fees		(791,000)
Net cash provided (used) by investing activities	11,537,000	(5,359,000)
Cash flows from financing activities:
Payments of long-term debt	(4,002,000)	(246,000)
Borrowings of long-term debt	1,106,000	6,193,000
Debt conversion to equity in subsidiary		840,000
Issuances of common stock, net of issuance costs		1,858,000
Net cash (used) provided by financing activities	(2,896,000)	8,645,000
Net decrease in cash	(5,558,000)	(2,784,000)
Cash and cash equivalents at beginning of period	19,290,000	56,595,000	$ 56,595,000
Cash and cash equivalents at end of period	$ 13,732,000	$ 53,811,000	$ 19,290,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1,594,000		$ 294,686,000	$ (132,384,000)	$ 163,896,000	$ 36,407,000	$ 200,304,000
Beginning balance, shares at Dec. 31, 2021	79,746,000
Net loss				(8,048,000)	(8,048,000)	(903,000)	(8,951,000)
Issuance of common stock, net of expenses	$ 98,000		1,760,000		1,858,000		1,858,000
Issuance of common stock, net of expenses, shares	4,881,000
Conversion of debt to equity in subsidiary						840,000	840,000
Stock based payments			4,000		4,000		4,000
Stock based payments, shares
Ending balance, value at Mar. 31, 2022	$ 1,692,000		296,450,000	(140,432,000)	157,710,000	36,344,000	194,055,000
Ending balance, shares at Mar. 31, 2022	84,627,000
Beginning balance, value at Dec. 31, 2022	$ 2,779,000		317,126,000	(194,343,000)	125,562,000	31,119,000	156,681,000
Beginning balance, shares at Dec. 31, 2022	139,017,000
Net loss				(8,035,000)	(8,035,000)	(598,000)	(8,633,000)
Ending balance, value at Mar. 31, 2023	$ 2,779,000		$ 317,126,000	$ (202,378,000)	$ 117,527,000	$ 30,521,000	$ 148,048,000
Ending balance, shares at Mar. 31, 2023	139,017,000

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct Marketing, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation, (8) Secure Living, and (9) Alternative Energy. Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation. (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing. (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy. On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp, Inc. (“APB”), which provided for an investment of $ 40,000,200 6,666,700 0.01 6.00 On September 13, 2021, the Company finalized a shareholder agreement between its subsidiary, DSS Financial Management, Inc. (“DFMI”) and HR1 Holdings Limited (“HR1”), a company incorporated in the British Virgin Islands, for the purpose of operating a vehicle for private and institutional investors seeking a highly liquid investment fund with attractive risk adjusted returns relative to market unpredictability and volatility. Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%. LVAM executes within reliable platforms and broad market access and uses proprietary systems and algorithms to trade liquid exchange-traded funds (ETFs), stocks, futures or crypto. Aimed at providing consistent returns while offering the unique ability to liquidate the portfolio within 5 to 10 minutes under normal market conditions, LVAM provides an array of advanced tools and products enabling customers to explore multiple opportunities, strengthen and diversify their portfolios, and meet their individual investing goals. On December 23, 2021, DSS purchased 50,000,000 0.06 47 58 On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 75 On January 24, 2022, DSS entered into a business consulting agreement with Sharing Services Global Corporation (“SHRG”). As part of this agreement, 50,000,000 65 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34 The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of March 31, 2023 and December 31, 2022, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2022 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation Use of Estimates Reclassifications - For the three months ended March 31, 2022, $ 577,000 Cash Equivalents Accounts Receivable 29,000 29,000 Notes receivable, unearned interest, and related recognition Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory 57,000 742,000 Impairment of Long-Lived Assets and Goodwill Business Combinations (Loss) Earnings Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive. For the three months ended March 31, 2023, potential dilutive instruments included warrants of 5,000 and for the three months ended March 31, 2022 potential dilutive instruments included both warrants and options of 3,556 11,930 Concentration of Credit Risk - As of December 31, 2022, two customers accounted for approximately 14 6 36 17 As of March 31, 2023, one customer accounted for approximately 23% of our consolidated revenue and 47 % of our trade accounts receivable balance. Income Taxes Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Going Concern 13.7 Aside from its $ 13.7 13.4 12 55 30 50 15 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 13.7 13.4 12

Revenue

Revenue	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of March 31, 2023, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amount less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At March 31, 2023, and December 31, 2022, the Company established a reserve for doubtful accounts of approximately $ 29,000 29,000 Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of March 31, 2023. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 14 for disaggregated revenue information.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory consisted of the following as of: Schedule of Inventory March 31, December 31, Finished Goods $ 5,596,000 $ 6,779,000 Work in Process 536,000 403,000 Raw Materials 1,187,000 1,281,000 Inventory Gross $ 7,319,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 7,262,000 $ 7,721,000

Notes Receivable

Notes Receivable	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Notes Receivable	4. Notes Receivable Note 1 On February 8, 2021, the Company entered into a convertible promissory note (“Note 1”) with Borrower 1, a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 4 Note 2 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 2”) with Borrower 2, a company registered in the state of Texas. Note 3 has an aggregate principal balance up to $ 5,000,000 6.65 May 1, 2023 Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion. 5,503,000 5,420,000 Note 3 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 3”) with Borrower 3, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 5.59 September 22, 2022 3,751,000 3,701,000 Note 4 On October 25, 2021, APB entered into loan agreement (“Note 4”) with Borrower 4, a company registered in the state of Utah. Note 4 has an initial aggregate principal balance up to $ 1,000,000 $3,000,000 8.0 October 25, 2022 This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. 884,000 896,000 896,000 Note 5 On May 14, 2021, APB extended the credit (“Note 5”) to an individual (“Borrower 5”) in the form of two promissory notes for $ 250,000 10,000 12.5 May 15, 2023 260,000 9,300 252,000 9,000 Note 6 On October 27, 2021, HWH World, Inc., a subsidiary of the Company entered a revolving loan commitment (“Note 6”) with Borrower 8, a company registered in Taiwan. Note 6 has a principal balance of $ 52,000 December 31, 2021 66,000 63,000 note was amended in April 2022 to borrow up to $ 102,000 18 Note 7 On December 28, 2021, APB entered into promissory note (“Note 7”) with Borrower 7, a company registered in the state of California. Note 8 has a principal balance of $ 700,000 12.0 December 28, 2022 May 31, 2023 707,000 701,000 Note 8 On January 24, 2022, APB and Borrower 8 entered into a promissory note (“Note 8”) in the principal sum of $ 100,000 6 January 2024 107,000 106,000 Note 9 On March 2, 2022, APB and Borrower 9, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 9”). Under the terms of Note 9, APB at its discretion, may lend up to the principal sum of $ 892,500 8 March 2024 766,000 23,000 376,000 874,000 25,000 Note 10 On May 9, 2022, DSS PureAir and Borrower 11 entered into a promissory note (“Note 10”) in the principal sum of $ 210,000 10 February 9, 2023 221,000 213,000 Note 11 On August 29, 2022, DSS Financial Management Inc and Borrower 11 entered into a promissory note (“Note 11”) in the principal sum of $ 100,000 8 August 29, 2025 101,000 100,000 Note 12 On July 26, 2022, APB and Borrower 12 entered into a promissory note (“Note 12”) in the principal sum of $ 1,000,000 8 July 26, 2024 440,000 80,000 924,000 66,000

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Financial Instruments	5. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 13,668,000 $ - $ 13,668,000 $ 13,668,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 20,195,000 (6,804,000 ) 13,391,000 - 13,391,000 - Level 2 Warrants 3,318,000 (3,174,000 ) 144,000 - - 144,000 Convertible securities 1,023,000 (979,000 ) 44,000 - - 44,000 Total $ 38,268,000 $ (10,957,000 ) $ 27,311,000 $ 13,732,000 $ 13,391,000 $ 188,000 2022 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

Provision for Credit Losses

Provision for Credit Losses	3 Months Ended
	Mar. 31, 2023
Provision For Credit Losses
Provision for Credit Losses	6 . Provision for Credit Losses Effective December 31, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” As of December 31, 2022, and March 31, 2023 we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. General Loan Portfolio Reserve - 145,000 Industry Portfolio Reserves - Specific Loan Reserves Previously, we had identified credit weaknesses and borrower repayment weakness in the Borrow 6 loan, which has a current principal and interest balance of $ 896,000 The following table identifies the loan loss reserve for the period ending March 31, 2023 and Schedule of Loan loss reserve General Loan Portfolio Reserve $ 145,000 Specific Loan Reserves $ 896,000 Total $ 1,041,000

Investments

Investments	3 Months Ended
	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Investments	7. Investments Alset International Limited related party The Company owns 127,179,291 4 2,289,000 3,319,000 1,156,000 305,000 West Park Capital, Inc. On October 10, 2019, the Company entered a convertible promissory note (“TBD Note”) with Century TBD Holdings, LLC (“TBD”), a Florida limited liability company. The Company loaned the principal sum of $ 500,000 , of which up to $ 500,000 and all accrued interest can be paid by an “Optional Conversion” of such amount up to 19.8 % (non-dilutable) of all outstanding membership interest in TBD. This TBD Note accrues interest at 6 % and matures on October 9, 2021 . On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and TBD where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 % of the issued and outstanding shares of West Park. This note and stock exchange agreement was finalized during the first quarter 2022 and valued at approximately $ 500,000 and is included in Investments on the consolidated balance sheet on December 31, 2022 and as of March 31, 2023. BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 20 4,300 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 1.00 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 of the available options under the Vivacitas Agreement #1 for $ 1,000,000 . This, along with the shares received as part Vivacitas Agreement #2 increased the Company’s equity position in Vivacitas to approximately 16 % as of December 31, 2022. As of December 31, 2022, the Company determined to impair 100 % of its investment in Vivacitas, in the amount of $ 4,100,000 . Stemtech Corporation In September 2021, the Company’s subsidiary SHRG, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which SHRG invested $ 1.4 million in Stemtech in exchange for: (a) a Convertible Promissory Note in the amount of $ 1.4 million in favor of the Company (the “Convertible Note”) and (b) a detachable Warrant to purchase shares GNTW common stock (the “GNTW Warrant”). Stemtech is a subsidiary of GNTW. As an inducement to enter into the SPA, GNTW agreed to pay to the SHRG an origination fee of $ 500,000 , payable in shares of GNTW’s common stock. The Convertible Note matures on September 9, 2024 , bears interest at the annual rate of 10 %, and is convertible, at the option of the holder, into shares of GNTW’s common stock at a conversion rate calculated based on the closing price per share of GNTW’s common stock during the 30-dayperiod ended September 19, 2021. The GNTW Warrant expires on September 13, 2024 and conveys the right to purchase up to 1.4 million shares of GNTW’s common stock at a purchase price calculated based on the closing price per share of GTNW’s common stock during the 10-day period ended September 13, 2021. In September 2021, GNTW issued to the Company 154,173 shares of its common stock, or less than 1% of the shares of GNTW then issued and outstanding, in payment of the origination fee. In November 2021, Globe Net Wireless Corp. changed its corporate name to Stemtech Corporation. In connection therewith, the investee’s common stock is now traded under the symbol “STEK”. The SHRG carries its investment in the Convertible Note, the GNTW Warrant and the shares of GNTW common stock at fair value in accordance with GAAP. investment in the the GNTW Warrant 144,000 44,000 140,000 39,000 In September 2021, SHRG entered into a Membership Unit Purchase Agreement pursuant to which the SHRG acquired a 30.75 1,537,000 100

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	8. Acquisitions Sentinel Brokers Company, Inc. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 300,000 750,000 1,050,000 Investments—Equity Method and Joint Ventures 50.1 75 The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 ) We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of Sentinel Co. Assets included in this acquisition are cash of $ 3,977,000 344,000 1,000 Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”).

Short-Term and Long-Term Debt

Short-Term and Long-Term Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Short-Term and Long-Term Debt	9. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 200,000 8.0 5.00 200,000 On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 1 111,000 On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 3,290,000 3,406,000 4.63 479,000 2,810,000 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 , with the amount financed approximating $ 5,105,000 . The Shelton Agreement contains monthly payments of principal and an initial interest 4.25 %. The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months with a balloon payment approximating $ 2,829,000 due at term end. The affective interest rate at December 31, 2022 was 4.25 %. The funds borrowed were used to purchase a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62 acre site. The purchase price has been allocated as $ 4,640,000 , $ 1,600,000 , and $ 325,000 for the facility, land, and tenant improvements respectively. Also include in the value of the property is $ 585,000 of intangible assets with an estimated useful life approximating 3 years. The net book value of these asset as of March 31, 2023 approximated $ 6,727,000 . Of the total financed, approximately $ 183,000 of principal and accrued interest is classified as current portion of long-term debt, net, and the remaining balance of approximately $ 4,790,000 recorded as long-term debt, net of $ 17,500 in deferred financing costs. On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,997,000 3,000,000 On October 27, 2021, HWH World, Inc., a subsidiary of the Company entered a revolving loan commitment (“Note 8”) with Borrower 8, a company registered in Taiwan. Note 8 has a principal balance of $ 52,000 December 31, 2021 66,000 63,000 18 On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 52,407,000 The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in ful 8.46 November 2, 2023 November 2, 2024 40,193,000 270,000 40,486,000 270,000 297,000 156,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 286,000 338,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4,500,000 3,200,000 1,000,000 222,000 29,000 5 4,450,000 25 4.28 69,000 2,982,000 23,000 5,000 On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust Company for the principal amount of $ 790,000 7.44 14,000 A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to December 31, 2022, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2023 $ 43,275,000 2024 3,801,000 2025 858,000 2026 901,000 2027 947,000 Thereafter 4,769,000

Lease Liability

Lease Liability	3 Months Ended
	Mar. 31, 2023
Lease Liability
Lease Liability	10. Lease Liability The Company has operating leases predominantly for operating facilities. As of March 31, 2023, the remaining lease terms on our operating leases range from less than one to five years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of March 31, 2023. Future minimum lease payments as of March 31, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2023 941,000 2024 1,050,000 2025 906,000 2026 899,000 2027 916,000 2028 935,000 2029 954,000 After 4,015,000 Total lease payments 10,616,000 Less: Imputed Interest (2,043,000 ) Present value of remaining lease payments $ 8,573,000 Current $ 800,000 Noncurrent $ 7,773,000 Weighted-average remaining lease term (years) 14.3 Weighted-average discount rate 4.3 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies License Agreement In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $ 1,250,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Equity	12. Stockholders’ Equity Sales of Equity On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On March 10, 2022, the Company issued 894,084 340,000 On May 5, 2022, the Company issued 63,205 29,000 On May 25, 2022, the Company issued 15,389,995 5,848,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.41 Stock-Based Compensation - 4,000

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	13. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the three-months ended March 31, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 249,000 $ 1,378,000

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information	14. Segment Information The Company’s nine businesses lines are organized, managed, and internally reported as five Our segment structure presented below represents a change from the prior year for the inclusion of our Biotechnology, Securities, and Commercial Lending segments and the removal of our Plastics segment, Digital Group and IP Technology Management segment as the Plastics segment was discontinued in 2020, DSS Digital was sold and discontinued in May 2021 and activities surrounding our IP Technology Management segment have significantly decreased. The amounts for these segments have been included in the corporate reporting segment for the year ended March 31, 2023 and 2022, as necessary, below for reconciliation purposes. Approximate information concerning the Company’s operations by reportable segment for the three months ended March 31, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended March 31, 2023 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 6,130,000 $ 117,000 $ 3,994,000 $ - $ 1,685,000 $ - $ 11,926,000 Depreciation and amortization 188,000 - 46,000 298,000 743,000 58,000 1,334,000 Interest expense 39,000 - - - 210,000 - 249,000 Interest Income - - 4,000 94,000 32,000 - 130,000 Net income (loss) from continuing operations 696,000 (564,000 ) (3,187,000 ) (848,000 ) (2,028,000 ) (2,702,000 ) (8,633,000 ) Capital expenditures 576,000 - (15,000 ) 5,000 28,000 - 594,000 Identifiable assets 25,217,000 43,133,000 20,539,000 52,983,000 76,003,000 8,875,000 226,750,000 Three Months Ended March 31,2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,569,000 $ 129,000 $ 6,932,000 $ - $ 1,674,000 $ - $ 12,304,000 Depreciation and amortization 180,000 - 48,000 278,000 2,685,000 74,000 3,266,000 Interest expense 24,000 - 687,000 - 801,000 - 802,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations (42,000 ) 181,000 (4,486,000 ) (616,000 ) (2,508,000 ) (1,480,000 ) (8,951,000 ) Capital expenditures 923,000 - 2,000 - 13,000 4,000 942,000 Identifiable assets 23,371,000 57,259,000 45,788,000 56,276,000 85,178,000 13,987,000 281,859,000 The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended March 31, 2023 Packaging Printing and Fabrication $ 5,865,000 Commercial and Security Printing 265,000 Total Printed Products $ 6,130,000 Three months ended March 31, 2022 Packaging Printing and Fabrication $ 3,516,000 Commercial and Security Printing 53,000 Total Printed Products $ 3,569,000 Direct Marketing Three months ended March 31, 2023 Direct Marketing Internet Sales $ 3,994,000 Total Direct Marketing $ 3,994,000 Three months ended March 31, 2022 Direct Marketing Internet Sales $ 6,932,000 Total Direct Marketing $ 6,932,000 Rental Income Three months ended March 31, 2023 Rental income $ 1,685,000 Total Rental Income $ 1,685,000 Three months ended March 31, 2022 Rental income $ 1,663,000 Total Rental Income $ 1,663,000 Management Fee Income Three months ended March 31, 2023 Management fee income $ - Total Management fee income $ - Three months ended March 31, 2022 Management fee income $ 11,000 Total Management fee income $ 11,000 Net Investment Income Three months ended March 31, 2023 Net investment income $ 117,000 Total Investment income $ 117,000 Three months ended March 31, 2022 Net Investment income $ 129,000 Total Investment income $ 129,000

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions The Company owns 127,179,291 4 2,289,000 3,319,000 1,156,000 1,590,000 On March 2, 2020, AMRE entered into a $ 200,000 8.0 5.00 200,000 On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”), a related party, to purchase from the Seller’s its wholly owned subsidiary Impact Oncology PTE Ltd. (“IOPL”) for a purchase price $ 2,480,000 2,480,000 250,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,997,000 8,000 On November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,469,000 21,366,177 8,350,000 367,400 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events On May 4, 2023, the Company distributed approximately 280 7

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Reclassifications	Reclassifications - For the three months ended March 31, 2022, $ 577,000
Cash Equivalents	Cash Equivalents
Accounts Receivable	Accounts Receivable 29,000 29,000
Notes receivable, unearned interest, and related recognition	Notes receivable, unearned interest, and related recognition
Investments	Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Inventory	Inventory 57,000 742,000
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
Business Combinations	Business Combinations
(Loss) Earnings Per Common Share	(Loss) Earnings Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive. For the three months ended March 31, 2023, potential dilutive instruments included warrants of 5,000 and for the three months ended March 31, 2022 potential dilutive instruments included both warrants and options of 3,556 11,930
Concentration of Credit Risk	Concentration of Credit Risk - As of December 31, 2022, two customers accounted for approximately 14 6 36 17 As of March 31, 2023, one customer accounted for approximately 23% of our consolidated revenue and 47 % of our trade accounts receivable balance.
Income Taxes	Income Taxes
Allowance For Loans And Lease Losses	Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses”
Going Concern	Going Concern 13.7 Aside from its $ 13.7 13.4 12 55 30 50 15 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 13.7 13.4 12

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following as of: Schedule of Inventory March 31, December 31, Finished Goods $ 5,596,000 $ 6,779,000 Work in Process 536,000 403,000 Raw Materials 1,187,000 1,281,000 Inventory Gross $ 7,319,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 7,262,000 $ 7,721,000

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Schedule of Cash and Marketable Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 13,668,000 $ - $ 13,668,000 $ 13,668,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 20,195,000 (6,804,000 ) 13,391,000 - 13,391,000 - Level 2 Warrants 3,318,000 (3,174,000 ) 144,000 - - 144,000 Convertible securities 1,023,000 (979,000 ) 44,000 - - 44,000 Total $ 38,268,000 $ (10,957,000 ) $ 27,311,000 $ 13,732,000 $ 13,391,000 $ 188,000 2022 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000

Provision for Credit Losses (Ta

Provision for Credit Losses (Tables)	3 Months Ended
	Mar. 31, 2023
Provision For Credit Losses
Schedule of Loan loss reserve	The following table identifies the loan loss reserve for the period ending March 31, 2023 and Schedule of Loan loss reserve General Loan Portfolio Reserve $ 145,000 Specific Loan Reserves $ 896,000 Total $ 1,041,000

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2023
Sentinel Brokers Company Inc [Member]
Business Acquisition [Line Items]
Schedule of Business Acquisition, Pro Forma Information	The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 )

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Notes Payable and Long-term Debt	A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to December 31, 2022, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2023 $ 43,275,000 2024 3,801,000 2025 858,000 2026 901,000 2027 947,000 Thereafter 4,769,000

Lease Liability (Tables)

Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2023
Lease Liability
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of March 31, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2023 941,000 2024 1,050,000 2025 906,000 2026 899,000 2027 916,000 2028 935,000 2029 954,000 After 4,015,000 Total lease payments 10,616,000 Less: Imputed Interest (2,043,000 ) Present value of remaining lease payments $ 8,573,000 Current $ 800,000 Noncurrent $ 7,773,000 Weighted-average remaining lease term (years) 14.3 Weighted-average discount rate 4.3 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the three-months ended March 31, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 249,000 $ 1,378,000

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three months ended March 31, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended March 31, 2023 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 6,130,000 $ 117,000 $ 3,994,000 $ - $ 1,685,000 $ - $ 11,926,000 Depreciation and amortization 188,000 - 46,000 298,000 743,000 58,000 1,334,000 Interest expense 39,000 - - - 210,000 - 249,000 Interest Income - - 4,000 94,000 32,000 - 130,000 Net income (loss) from continuing operations 696,000 (564,000 ) (3,187,000 ) (848,000 ) (2,028,000 ) (2,702,000 ) (8,633,000 ) Capital expenditures 576,000 - (15,000 ) 5,000 28,000 - 594,000 Identifiable assets 25,217,000 43,133,000 20,539,000 52,983,000 76,003,000 8,875,000 226,750,000 Three Months Ended March 31,2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,569,000 $ 129,000 $ 6,932,000 $ - $ 1,674,000 $ - $ 12,304,000 Depreciation and amortization 180,000 - 48,000 278,000 2,685,000 74,000 3,266,000 Interest expense 24,000 - 687,000 - 801,000 - 802,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations (42,000 ) 181,000 (4,486,000 ) (616,000 ) (2,508,000 ) (1,480,000 ) (8,951,000 ) Capital expenditures 923,000 - 2,000 - 13,000 4,000 942,000 Identifiable assets 23,371,000 57,259,000 45,788,000 56,276,000 85,178,000 13,987,000 281,859,000
Schedule of Disaggregation of Revenue	Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended March 31, 2023 Packaging Printing and Fabrication $ 5,865,000 Commercial and Security Printing 265,000 Total Printed Products $ 6,130,000 Three months ended March 31, 2022 Packaging Printing and Fabrication $ 3,516,000 Commercial and Security Printing 53,000 Total Printed Products $ 3,569,000 Direct Marketing Three months ended March 31, 2023 Direct Marketing Internet Sales $ 3,994,000 Total Direct Marketing $ 3,994,000 Three months ended March 31, 2022 Direct Marketing Internet Sales $ 6,932,000 Total Direct Marketing $ 6,932,000 Rental Income Three months ended March 31, 2023 Rental income $ 1,685,000 Total Rental Income $ 1,685,000 Three months ended March 31, 2022 Rental income $ 1,663,000 Total Rental Income $ 1,663,000 Management Fee Income Three months ended March 31, 2023 Management fee income $ - Total Management fee income $ - Three months ended March 31, 2022 Management fee income $ 11,000 Total Management fee income $ 11,000 Net Investment Income Three months ended March 31, 2023 Net investment income $ 117,000 Total Investment income $ 117,000 Three months ended March 31, 2022 Net Investment income $ 129,000 Total Investment income $ 129,000

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)								3 Months Ended		12 Months Ended
	May 17, 2022	Mar. 09, 2022	Feb. 28, 2022	Jan. 24, 2022	Dec. 23, 2021	Sep. 13, 2021	Sep. 09, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jul. 02, 2022	Jul. 01, 2022	Feb. 18, 2022	Dec. 31, 2021	Dec. 22, 2021	May 13, 2021
Common stock par value								$ 0.02		$ 0.02
Issuance of common stock, net									$ 1,858,000
Number of shares issued for acquisition	17,570,948
Reclassification from interest expense								$ 577,000
Reserve for doubtful accounts								29,000		$ 29,000
Inventory allowance for obsolescence								57,000		742,000
Cash								13,732,000		19,290,000
Marketable securities								13,391,000		27,307,000				$ 13,400,000
Outstanding principal and interest								12,000,000
Outstanding principal and interest on notes receivable								11,422,000	$ 12,000,000	$ 11,719,000
Underwriters [Member] | Minimum [Member]
Sale of stock consideration received on transaction								30,000,000
Underwriters [Member] | Maximum [Member]
Sale of stock consideration received on transaction								$ 50,000,000
Impact BioMedical, Inc. [Member]
Ownership percentage								55%
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration risk, rate								23%		14%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration risk, rate								47%		36%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration risk, rate										6%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration risk, rate										17%
Warrant [Member]
Anti dilutive securities excluded from computation of EPS								5,000	3,556
Share-Based Payment Arrangement, Option [Member]
Anti dilutive securities excluded from computation of EPS									11,930
Alset EHome International, Inc. [Member]
Shares issued for convertible debt	21,366,177
Unpaid interest	$ 367,000
Alset International Limited [Member]
Shares issued for convertible debt	21,366,177
American Medical REIT Inc. [Member]
Debt instrument, face amount	$ 8,350,000
Unpaid interest	$ 367,000
Alset EHome [Member]
Share price											$ 0.34	$ 0.34
Sharing Services Global Corp [Member]
Sale of stock consideration received on transaction								$ 15,000,000
Pinnacle Bank [Member]
Debt instrument, face amount								$ 40,200,000
Sharing Services Global Corp [Member]
Equity method investment description of principal activities					On December 23, 2021, DSS purchased 50,000,000 shares at $0.06 per share of Sharing Services Global Corporation (“SHRG”) via a private placement. With this purchase, DSS increased its ownership of voting shares from approximately 47% of SHRG to approximately 58%.
Equity method investment ownership percentage					58%										47%
Sentinel Brokers LLC [Member]
Equity method investment ownership percentage										75%						24.90%
Consulting Agreement [Member] | Warrant [Member]
Equity method investment ownership percentage				65%
Sharing Services Global Corp [Member]
Stock repurchased during period, shares					50,000,000
Share price					$ 0.06
True Partners Capital Holdings Limited [Member]
Share price													$ 0.41
Number of shares issued for acquisition	62,122,908
Stock Purchase Agreement [Member]
Issuance of common stock, net, shares		3,986,877	44,619,423
Shares issued price per share			$ 0.3810
Issuance of common stock, net		$ 1,519,000	$ 17,000,000
Stock Purchase Agreement [Member] | Alset EHome International, Inc. [Member]
Issuance of common stock, net, shares		3,986,877	44,619,423
Shares issued price per share			$ 0.3810
Issuance of common stock, net		$ 1,519,000	$ 17,000,000
Employee stock purchase plans			3,986,877
Payments for proceeds from previous acquisition			$ 1,519,000
Stock Purchase Agreement [Member] | American Pacific Bancorp [Member]
Investment amount							$ 40,000,200
Number of shares issued on investment							6,666,700
Business acquisition, share price							$ 6
Stock Purchase Agreement [Member] | American Pacific Bancorp [Member] | Common Class A [Member]
Common stock par value							$ 0.01
Stock Purchase Agreement [Member] | Liquid Asset Limited Management Limited [Member]
Business acquisition, description						Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%. LVAM executes within reliable platforms and broad market access and uses proprietary systems and algorithms to trade liquid exchange-traded funds (ETFs), stocks, futures or crypto. Aimed at providing consistent returns while offering the unique ability to liquidate the portfolio within 5 to 10 minutes under normal market conditions, LVAM provides an array of advanced tools and products enabling customers to explore multiple opportunities, strengthen and diversify their portfolios, and meet their individual investing goals.
Consulting Agreement [Member] | Warrant [Member]
Stock issued during period shares issued for services				50,000,000

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Reserve for doubtful accounts	$ 29,000	$ 29,000

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished Goods	$ 5,596,000	$ 6,779,000
Work in Process	536,000	403,000
Raw Materials	1,187,000	1,281,000
Inventory Gross	7,319,000	8,463,000
Less allowance for obsolescence	(57,000)	(742,000)
Inventory Net	$ 7,262,000	$ 7,721,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Aug. 29, 2022

Jul. 26, 2022

May 09, 2022

Mar. 02, 2022

Jan. 24, 2022

Dec. 29, 2021

Dec. 28, 2021

Oct. 27, 2021

Oct. 25, 2021

Sep. 23, 2021

May 14, 2021

Apr. 30, 2022

Mar. 31, 2023

Dec. 31, 2022

Mar. 31, 2022

Feb. 08, 2021

Financing Receivable, Modified [Line Items]

Notes receivable current

$ 11,422,000

$ 11,719,000

$ 12,000,000

Notes receivable

158,000

922,000

Note 1 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 800,000

Debt interest rate

4%

Note 2 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 5,000,000

Debt interest rate

6.65%

Maturity date

May 01, 2023

Debt conversion description

Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion.

Notes receivable current

5,503,000

5,420,000

Note 3 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 3,500,000

Debt interest rate

5.59%

Maturity date

Sep. 22, 2022

Notes receivable current

3,751,000

3,701,000

Note 4 [Member]

Financing Receivable, Modified [Line Items]

Debt interest rate

8%

Maturity date

Oct. 25, 2022

Notes receivable current

884,000

896,000

Maximum principal borrowing amount

$ 3,000,000

Debt description

This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest.

Reserve on notes

896,000

Note 4 [Member] | Maximum [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 1,000,000

Note 5 [Member]

Financing Receivable, Modified [Line Items]

Debt interest rate

12.50%

Maturity date

May 15, 2023

Note 5 [Member] | Promissory Note One [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 250,000

Notes receivable current

260,000

Notes receivable

252,000

Note 5 [Member] | Promissory Note Two [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 10,000

Notes receivable current

9,300

Notes receivable

9,000

Note 6 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 52,000

Debt interest rate

18%

Maturity date

Dec. 31, 2021

Notes receivable current

66,000

63,000

Maximum principal borrowing amount

$ 102,000

Debt description

note was amended in April 2022 to borrow up to $102,000 and extend the maturity date through April 2023 bearing interest rate of 18%. The due date of this loan is currently being re-negotiated.

Note 7 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 700,000

Debt interest rate

12%

Maturity date

May 31, 2023

Dec. 28, 2022

Notes receivable current

707,000

701,000

Note 8 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 100,000

Debt interest rate

6%

Notes receivable

107,000

106,000

Debt instrument, face amount

January 2024

Note 9 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 892,500

Debt interest rate

8%

Notes receivable current

376,000

Debt instrument, face amount

March 2024

Outstanding principal and interest

766,000

Unamortized origination fees

23,000

25,000

Notes payable

874,000

Note 10 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 210,000

Debt interest rate

10%

Maturity date

Feb. 09, 2023

Notes receivable current

221,000

Notes payable

213,000

Note 11 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 100,000

Debt interest rate

8%

Maturity date

Aug. 29, 2025

Notes receivable

100,000

Notes payable

101,000

Note 12 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 1,000,000

Debt interest rate

8%

Maturity date

Jul. 26, 2024

Outstanding principal and interest

440,000

Unamortized origination fees

$ 80,000

66,000

Notes payable

$ 924,000

Schedule of Cash and Marketable

Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 38,268,000	$ 59,894,000
Unrealized Gain/(Loss)	(10,957,000)	(3,659,000)
Fair Value	27,311,000	46,776,000
Cash and Cash Equivalents	13,732,000	19,290,000
Marketable Securities	13,391,000	27,307,000
Investments	188,000	179,000
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	1,023,000	1,023,000
Unrealized Gain/(Loss)	(979,000)
Fair Value	44,000	39,000
Cash and Cash Equivalents
Marketable Securities
Investments	44,000	39,000
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	3,318,000	3,318,000
Unrealized Gain/(Loss)	(3,174,000)
Fair Value	144,000	140,000
Cash and Cash Equivalents
Marketable Securities
Investments	144,000	140,000
Cash [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	13,668,000	19,226,000
Unrealized Gain/(Loss)
Fair Value	13,668,000	19,226,000
Cash and Cash Equivalents	13,668,000	19,226,000
Marketable Securities
Investments
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	64,000	64,000
Unrealized Gain/(Loss)
Fair Value	64,000	64,000
Cash and Cash Equivalents	64,000	64,000
Marketable Securities
Investments
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	20,195,000	36,263,000
Unrealized Gain/(Loss)	(6,804,000)	(3,659,000)
Fair Value	13,391,000	27,307,000
Cash and Cash Equivalents
Marketable Securities	13,391,000	27,307,000
Investments

Schedule of Loan loss reserve (

Schedule of Loan loss reserve (Details) - American Pacific Bancorp [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
General Loan Portfolio Reserve [Member]
Financing Receivable, Credit Quality Indicator [Line Items]
Total	$ 145,000
Nonperforming Financial Instruments [Member]
Financing Receivable, Credit Quality Indicator [Line Items]
Total	$ 1,041,000	$ 1,041,000
Nonperforming Financial Instruments [Member] | General Loan Portfolio Reserve [Member]
Financing Receivable, Credit Quality Indicator [Line Items]
Total		145,000
Nonperforming Financial Instruments [Member] | Specific Loan Reserves [Member]
Financing Receivable, Credit Quality Indicator [Line Items]
Total		$ 896,000

Provision for Credit Losses (De

Provision for Credit Losses (Details Narrative) - American Pacific Bancorp [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
General Loan Portfolio Reserve [Member]
Financing Receivable, Past Due [Line Items]
Portfolio reserve	$ 145,000
Specific Loan Reserves [Member] | Asili LLC [Member]
Financing Receivable, Past Due [Line Items]
Non accrual loan balance	$ 896,000

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)									1 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Jul. 22, 2021	Apr. 01, 2021	Mar. 18, 2021	Mar. 15, 2021	Dec. 30, 2020	Dec. 19, 2020	Sep. 10, 2020	Oct. 10, 2019	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2021	Dec. 31, 2022
Unrealized loss on investments										$ (10,957,000)			$ (3,659,000)
Convertible Debt										12,000,000
Investments										188,000			179,000
Issuance of common stock, net of expenses											$ 1,858,000
Investments equity method										157,000			162,000
Proceeds from Issuance of common stock											1,858,000
Vivacitas Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	1,000,000
Stock Issued During Period, Value, Stock Options Exercised	$ 1,000,000
Investment ownership percentage	100%									100%
Investment Owned, Cost													$ 4,100,000
Common Stock [Member]
Issuance of common stock, net of expenses											$ 98,000
Issuance of common stock, net of expenses, shares											4,881,000
BMI Capital International LLC [Member]
Issuance of common stock, net of expenses							$ 100,000
Investments equity method										$ 4,300
Impact Oncology PTE Ltd. [Member]
Owners shares			2,480,000
Options to purchase additional shares			250,000
Consideration transferred			$ 2,480,000
Stemtech Corporation [Member] | Securities Purchase Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage									10%			10%
Debt Instrument, Maturity Date												Sep. 09, 2024
Investments									$ 1,400,000			$ 1,400,000
Consideration transferred												1,400,000
[custom:ConvertiblePromissoryNote-0]									$ 1,400,000			1,400,000
[custom:OriginationFee]												$ 500,000
Stockholders' Equity, Other Shares												154,173
Warrant										144,000			140,000
Convertible note										$ 44,000			$ 39,000
DSS Securities, Inc. [Member]
Equity method investment ownership percentage							14.90%
BMI Capital International LLC [Member]
Equity method investment ownership percentage							24.90%
BioMed Technologies Asia Pacific Holdings Limited [Member]
Equity method investment ownership percentage						4.99%
Issuance of common stock, net of expenses						$ 632,000
Issuance of common stock, net of expenses, shares						525
Vivacitas Oncology Inc [Member] | Vivacitas Agreement [Member]
Equity method investment ownership percentage													16%
Moji Life LLC [Member] | Membership Unit Purchase Agreement [Member]
Equity method investment ownership percentage									30.75%			30.75%
Payments to acquire equity method investments									$ 1,537,000
Minimum [Member] | BMI Capital International LLC [Member]
Equity method investment ownership percentage							20%
Alset International Limited [Member]
Owners shares										127,179,291			127,179,291
Outstanding share percentage													4%
Marketable securities										$ 2,289,000			$ 3,319,000
Unrealized loss on investments										1,156,000			1,590,000
Alset International Limited [Member] | Executive Director And Chief Executive Officer [Member].
Unrealized loss on investments										1,156,000	$ 305,000
Century TBD Holdings, LLC [Member]
Convertible Debt								$ 500,000
Debt Instrument, Interest Rate, Stated Percentage								6%
Debt Instrument, Maturity Date								Oct. 09, 2021
Century TBD Holdings, LLC [Member] | Maximum [Member]
Convertible Debt								$ 500,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger								19.80%
West Park Capital Inc [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger					7.50%
Investments										$ 500,000			$ 500,000
DSS Securities, Inc. [Member]
Issuance of common stock, net of expenses							$ 100,000
Outstanding membership interest							10%
Vivacitas Oncology Inc [Member]
Options to purchase additional shares				1,500,000
Shares issued, price per share				$ 1
Additional price per share				$ 1
Proceeds from Issuance of common stock				$ 500,000
Consideration transferred		$ 120,000
Sale of stock, description		the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022
Share Price		$ 1
Vivacitas Oncology Inc [Member] | Common Stock [Member]
Options to purchase additional shares				500,000

Schedule of Business Acquisitio

Schedule of Business Acquisition, Pro Forma Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares
Business Combination and Asset Acquisition [Abstract]
Revenue | $	$ 49,076,804
Net loss | $	$ (61,680,088)
Basic loss per share | $ / shares	$ (0.55)
Diluted loss per share | $ / shares	$ (0.55)

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Sep. 30, 2021	May 13, 2021	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Investments			$ 188,000	$ 179,000
Sentinel Brokers Company Inc [Member]
Business Acquisition [Line Items]
Purchae price		$ 300,000
Contribution of capital	$ 750,000
Investments	$ 1,050,000
Sentinel Brokers Company Inc [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Percentage of outstanding common stock		50.10%
American Pacific Bancorp [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents				3,977,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables				344,000
Fixed assets				$ 1,000
Sentinel Brokers Company Inc [Member]
Business Acquisition [Line Items]
Ownership percent		24.90%		75%

Schedule of Notes Payable and L

Schedule of Notes Payable and Long-term Debt (Details)	Mar. 31, 2023 USD ($)
Debt Disclosure [Abstract]
2023	$ 43,275,000
2024	3,801,000
2025	858,000
2026	901,000
2027	947,000
Thereafter	$ 4,769,000

Short-Term and Long-Term Debt_2

Short-Term and Long-Term Debt (Details Narrative)

1 Months Ended

3 Months Ended

12 Months Ended

May 17, 2022 USD ($) shares

Mar. 17, 2022 USD ($)

Nov. 02, 2021 USD ($)

Oct. 27, 2021 USD ($)

Oct. 13, 2021 USD ($)

Aug. 01, 2021 USD ($)

Mar. 16, 2021 USD ($)

Nov. 30, 2021 USD ($)

Mar. 31, 2023 USD ($)

Mar. 31, 2022 USD ($)

Dec. 31, 2022 USD ($)

Mar. 30, 2023 USD ($)

Dec. 31, 2021 USD ($)

Aug. 01, 2021 USD ($)

Aug. 01, 2021 a

Aug. 01, 2021 ft²

Aug. 01, 2021

May 20, 2021 USD ($)

Mar. 02, 2020 USD ($) $ / shares

Short-Term Debt [Line Items]

Long term debt current

$ 48,773,000

$ 47,161,000

Payments to acquire assets

594,000

$ 942,000

Interest expense

249,000

$ 802,000

BMIC Loan [Member]

Short-Term Debt [Line Items]

Principal amount

$ 3,000,000

512,000

3,000,000

Maturity date

Oct. 12, 2022

Wilson Loan [Member]

Short-Term Debt [Line Items]

Principal amount

$ 3,000,000

1,997,000

3,000,000

Maturity date

Oct. 12, 2022

Interest expense

8,000

Security Agreement [Member]

Short-Term Debt [Line Items]

Principal amount

$ 790,000

Principal interest percentage

7.44%

Interest Expense, Debt

14,000

American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Principal amount

$ 8,350,000

Principal interest percentage

1%

Proceeds from Paycheck Protection Program

$ 110,000

Long term debt

$ 111,000

Premier Packaging Bank Of America NA [Member]

Short-Term Debt [Line Items]

Principal amount

3,290,000

$ 3,406,000

Principal interest percentage

4.63%

Long term debt

2,810,000

Debt Financing Amount

$ 3,710,000

Long term debt current

479,000

AMRE Shelton LLC [Member] | Loan Agreement [Member]

Short-Term Debt [Line Items]

Principal amount

$ 6,155,000

Principal interest percentage

4.25%

Long term debt

4,790,000

Long term debt current

183,000

5,105,000

Debt instrument description

The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 2,829,000

Debt effective interest rate percentage

4.25%

Area of Land

13.62

40,000

Payments to acquire assets

6,727,000

Payments to intangible assets

$ 585,000

Debt issuance costs

17,500

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Facility [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

4,640,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Land [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

1,600,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Tenant Improvements [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 325,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Other Intangible Assets [Member]

Short-Term Debt [Line Items]

Estimated useful life

3 years

HWH World Inc. [Member]

Short-Term Debt [Line Items]

Principal amount

$ 52,000

$ 66,000

$ 63,000

Principal interest percentage

18%

Maturity date

Dec. 31, 2021

Pinnacle Bank [Member]

Short-Term Debt [Line Items]

Principal amount

$ 40,200,000

Pinnacle Bank [Member] | LifeCare Agreement [Member]

Short-Term Debt [Line Items]

Principal amount

$ 40,300,000

40,486,000

40,193,000

Debt instrument description

The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in ful

Debt effective interest rate percentage

8.46%

Payments to acquire assets

52,407,000

Payments to intangible assets

$ 15,901,000

Debt issuance costs

270,000

270,000

Maturity date

Nov. 02, 2023

Purchase price

$ 62,000,000

Interest expense

297,000

$ 156,000

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Extended Maturity [Member]

Short-Term Debt [Line Items]

Maturity date

Nov. 02, 2024

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Minimum [Member]

Short-Term Debt [Line Items]

Estimated useful life

1 year

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Estimated useful life

11 years

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Facility [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 32,100,000

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Land [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

12,100,000

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Site Improvements [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 1,500,000

Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

Principal interest percentage

8%

Class of warrant exercise price per share | $ / shares

$ 5

Warrants and rights outstanding

$ 200,000

Alset Note [Member]

Short-Term Debt [Line Items]

Principal amount

$ 8,350,000

$ 8,350,000

8,350,000

8,469,000

Principal interest percentage

8%

Long term debt

8,805,000

Interest expense

286,000

338,000

Debt instrument, maturity date description

matures in December 2023

Shares issued for convertible debt | shares

21,366,177

Accrued unpaid interest

$ 367,400

119,000

Pinnacle Loan [Member]

Short-Term Debt [Line Items]

Principal amount

$ 2,990,000

69,000

Principal interest percentage

4.28%

Payments to acquire assets

4,450,000

Payments to intangible assets

$ 29,000

Estimated useful life

5 years

Debt issuance costs

$ 2,982,000

Maturity date

Mar. 07, 2024

Purchase price

$ 4,500,000

Interest expense

$ 23,000

$ 5,000

Debt instrument term

25 years

Pinnacle Loan [Member] | Facility [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 3,200,000

Pinnacle Loan [Member] | Land [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

1,000,000

Pinnacle Loan [Member] | Site and Tenant Improvements [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 222,000

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Lease Liability
2023	$ 941,000
2024	1,050,000
2025	906,000
2026	899,000
2027	916,000
2028	935,000
2029	954,000
After	4,015,000
Total lease payments	10,616,000
Less: Imputed Interest	(2,043,000)
Present value of remaining lease payments	8,573,000
Current	800,000	$ 796,000
Noncurrent	$ 7,773,000	$ 7,820,000
Weighted-average remaining lease term (years)	14 years 3 months 18 days
Weighted-average discount rate	4.30%

Lease Liability (Details Narrat

Lease Liability (Details Narrative)	3 Months Ended
	Mar. 31, 2022 USD ($)
Minimum [Member]
Operating lease payment	$ 61,000
Maximum [Member]
Operating lease payment	$ 78,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - License Agreement [Member] - Bio Medical [Member]	Mar. 19, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loss contingency allegations	In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of March 31, 2023 and December 31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and no reasonable amount can be estimated
Research and development expense	$ 1,250,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)							3 Months Ended
	May 25, 2022	May 17, 2022	May 05, 2022	Mar. 10, 2022	Mar. 09, 2022	Feb. 28, 2022	Mar. 31, 2023	Mar. 31, 2022	Feb. 18, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock, value								$ 1,858,000
Stock Issued During Period, Shares, Acquisitions		17,570,948
Stock based compensation								$ 4,000
True Partners Capital Holdings Limited [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, Acquisitions		62,122,908
Share Price									$ 0.41
Alset EHome International, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued for convertible debt		21,366,177
Shares issued for convertible debt, value		$ 8,350,000
Accrued unpaid interest		$ 367,000
Stock Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock					3,986,877	44,619,423
Issued price per share						$ 0.3810
Number of shares of common stock, value					$ 1,519,000	$ 17,000,000
Stock Purchase Agreement [Member] | Alset EHome International, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock					3,986,877	44,619,423
Issued price per share						$ 0.3810
Number of shares of common stock, value					$ 1,519,000	$ 17,000,000
Employment Agreement [Member] | Heng Fai Ambrose Chan [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock	15,389,995			894,084
Number of shares of common stock, value	$ 5,848,000			$ 340,000
Employment Agreement [Member] | Frank Heuszel [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock			63,205
Number of shares of common stock, value			$ 29,000

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 249,000	$ 1,378,000

Schedule of Operations by Repor

Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 11,926,000	$ 12,304,000
Depreciation and amortization	1,334,000	3,266,000
Interest expense	249,000	802,000
Interest Income	130,000
Net income (loss) from continuing operations	(8,633,000)	(8,951,000)
Capital expenditures	594,000	942,000
Identifiable assets	226,750,000	281,859,000
Stock based compensation		4,000
Operating Segments [Member] | Product Packaging [Member]
Segment Reporting Information [Line Items]
Revenue	6,130,000	3,569,000
Depreciation and amortization	188,000	180,000
Interest expense	39,000	24,000
Interest Income
Net income (loss) from continuing operations	696,000	(42,000)
Capital expenditures	576,000	923,000
Identifiable assets	25,217,000	23,371,000
Stock based compensation		1,000
Operating Segments [Member] | Commercial Banking [Member]
Segment Reporting Information [Line Items]
Revenue	117,000	129,000
Depreciation and amortization
Interest expense
Interest Income
Net income (loss) from continuing operations	(564,000)	181,000
Capital expenditures
Identifiable assets	43,133,000	57,259,000
Stock based compensation
Operating Segments [Member] | Direct Marketing Online Sales [Member]
Segment Reporting Information [Line Items]
Revenue	3,994,000	6,932,000
Depreciation and amortization	46,000	48,000
Interest expense		687,000
Interest Income	4,000
Net income (loss) from continuing operations	(3,187,000)	(4,486,000)
Capital expenditures	(15,000)	2,000
Identifiable assets	20,539,000	45,788,000
Stock based compensation
Operating Segments [Member] | Biotechnology [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	298,000	278,000
Interest expense
Interest Income	94,000
Net income (loss) from continuing operations	(848,000)	(616,000)
Capital expenditures	5,000
Identifiable assets	52,983,000	56,276,000
Stock based compensation
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Revenue	1,685,000	1,674,000
Depreciation and amortization	743,000	2,685,000
Interest expense	210,000	801,000
Interest Income	32,000
Net income (loss) from continuing operations	(2,028,000)	(2,508,000)
Capital expenditures	28,000	13,000
Identifiable assets	76,003,000	85,178,000
Stock based compensation
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	58,000	74,000
Interest expense
Interest Income
Net income (loss) from continuing operations	(2,702,000)	(1,480,000)
Capital expenditures		4,000
Identifiable assets	$ 8,875,000	13,987,000
Stock based compensation		$ 3,000

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total Printed Products	$ 6,130,000	$ 3,569,000
Direct Marketing	3,994,000	6,932,000
Total Rental Income	1,685,000	1,663,000
Total Management fee income		11,000
Total Net Investment Income	117,000	129,000
Packaging Printing and Fabrication [Member]
Segment Reporting Information [Line Items]
Total Printed Products	5,865,000	3,516,000
Commercial and Security Printing [Member]
Segment Reporting Information [Line Items]
Total Printed Products	265,000	53,000
Direct Marketing Internet Sales [Member]
Segment Reporting Information [Line Items]
Direct Marketing	3,994,000	6,932,000
Rental Income [Member]
Segment Reporting Information [Line Items]
Total Rental Income	1,685,000	1,663,000
Management Fee Income [Member]
Segment Reporting Information [Line Items]
Total Management fee income		11,000
Net Investment Income [Member]
Segment Reporting Information [Line Items]
Total Net Investment Income	$ 117,000	$ 129,000

Segment Information (Details Na

Segment Information (Details Narrative)	9 Months Ended
	Sep. 30, 2022 Segments
Segment Reporting [Abstract]
Number of operating segments	5

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)								1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 09, 2022	May 17, 2022	Mar. 09, 2022	Feb. 28, 2022	Oct. 13, 2021	Mar. 18, 2021	Oct. 31, 2017	Nov. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jul. 02, 2022	Jul. 01, 2022	Feb. 18, 2022	Mar. 16, 2021	Mar. 02, 2020
Unrealized loss on investment									$ (10,957,000)		$ (3,659,000)
Debt instrument, face amount									249,000	$ 802,000
Issuance of common stock, net of expenses										1,858,000
Number of shares issued for acquisition		17,570,948
BMIC Loan [Member]
Principal amount					$ 3,000,000				512,000		3,000,000
Debt instrument maturity date					Oct. 12, 2022
Wilson Loan [Member]
Principal amount					$ 3,000,000				1,997,000		3,000,000
Debt instrument maturity date					Oct. 12, 2022
Debt instrument, face amount									8,000
Stock Purchase Agreement [Member]
Number of shares of common stock			3,986,877	44,619,423
Issued price per share				$ 0.3810
Issuance of common stock, net of expenses			$ 1,519,000	$ 17,000,000
Impact Oncology PTE Ltd. [Member]
Investment owned balance shares						2,480,000
Consideration transferred						$ 2,480,000
Options to purchase additional shares						250,000
True Partners Capital Holdings Limited [Member]
Number of shares issued for acquisition		62,122,908
Share price														$ 0.41
Alset Note [Member]
Principal amount		$ 8,350,000						$ 8,350,000	8,350,000		$ 8,469,000
Debt interest rate								8%
Debt instrument, face amount									286,000	$ 338,000
Debt instrument maturity date, description								matures in December 2023
Shares issued for convertible debt		21,366,177
Accrued unpaid interest		$ 367,400							$ 119,000
Alset International Limited [Member]
Investment owned balance shares									127,179,291		127,179,291
Warrants percentage									4%
Marketable securities									$ 2,289,000		$ 3,319,000
Unrealized loss on investment									$ 1,156,000		$ 1,590,000
Shares issued for convertible debt		21,366,177
American Medical REIT Inc. [Member]
Principal amount		$ 8,350,000
Debt interest rate															1%
American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member]
Principal amount																$ 200,000
Debt interest rate																8%
Exercise price of warrants																$ 5
Warrants and rights outstanding																$ 200,000
HWH International Inc [Member]
Principal amount							$ 50,000
Issued price per share							$ 0.15
Conversion of stock							333,333
Warrants to purchase							333,333
Cancelleation of warrants and notes	$ 78,635.62
Alset EHome [Member]
Share price												$ 0.34	$ 0.34

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		3 Months Ended
	May 05, 2023	Mar. 31, 2023	Mar. 31, 2022	May 04, 2023
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock			$ 1,858,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock	$ 280,000,000
Subsequent Event [Member] | S H R G [Member]
Subsequent Event [Line Items]
Equity Method Investment, Ownership Percentage				7%